ArticleJournal of biopharmaceutical statistics2012
Power and sample size calculation for microarray studies.
Article in Journal of biopharmaceutical statistics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Microarray Analysis of Visceral Adipose Tissue in Obese Women Reveals Common Crossroads Among Inflammation, Metabolism, Addictive Behaviors, and Cancer: AKT3 and MAPK1 Cross Point in Obesity.Journal of obesity · 2024Article
- Transcriptomic alterations in hypertrophy of the ligamentum flavum: interactions of Rho GTPases, RTK, PIK3, and FGF.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2023Article
- Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia.Turkish journal of medical sciences · 2022Article
- Statistical analysis in metabolic phenotyping.Nature protocols · 2021Article
- Article
- RNASeqDesign: A framework for RNA-Seq genome-wide power calculation and study design issues.Journal of the Royal Statistical Society. Series C, Applied statistics · 2019Article
- Evaluation of the effects of miRNAs in familial Mediterranean fever.Clinical rheumatology · 2019Article
- MetaboAnalyst 3.0--making metabolomics more meaningful.Nucleic acids research · 2015Article
- Statistical Issues in the Design and Analysis of nCounter Projects.Cancer informatics · 2014Review
- Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes.Genetic epidemiology · 2013Article
- Statistical considerations for analysis of microarray experiments.Clinical and translational science · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Microarray is a technology to screen a large number of genes to discover those differentially expressed between clinical subtypes or different conditions of human diseases. Gene discovery using microarray data requires adjustment for the large-scale multiplicity of candidate genes. The family-wise error rate (FWER) has been widely chosen as a global type I error rate adjusting for the multiplicity. Typically in microarray data, the expression levels of different genes are correlated because of coexpressing genes and the common experimental conditions shared by the genes on each array. To accurately control the FWER, the statistical testing procedure should appropriately reflect the dependency among the genes. Permutation methods have been used for accurate control of the FWER in analyzing microarray data. It is important to calculate the required sample size at the design stage of a new (confirmatory) microarray study. Because of the high dimensionality and complexity of the correlation structure in microarray data, however, there have been no sample size calculation methods accurately reflecting the true correlation structure of real microarray data. We propose sample size and power calculation methods that are useful when pilot data are available to design a confirmatory experiment. If no pilot data are available, we recommend a two-stage sample size recalculation based on our proposed method using the first stage data as pilot data. The calculated sample sizes are shown to accurately maintain the power through simulations. A real data example is taken to illustrate the proposed method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.